Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53|
- Stem cell function [ Time Frame: at one time study visit ] [ Designated as safety issue: No ]Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
- CD34+ cells assays [ Time Frame: at one time study visit ] [ Designated as safety issue: No ]Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.
Biospecimen Retention: Samples Without DNA
CD34+ cells isolated from the peripheral blood Splenic CD34+ cells
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||August 2015|
|Estimated Primary Completion Date:||August 2015 (Final data collection date for primary outcome measure)|
PV or ET
subject who has polycythemia vera or essential thrombocythemia
Procedure: Blood specimen
4 green top tube 40 cc of blood draw
Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01970930
|Contact: Jill Kleczko, MPAfirstname.lastname@example.org|
|Contact: Ronald Hoffman, MDemail@example.com|
|United States, New York|
|Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Principal Investigator: Ronald Hoffman, MD|
|Principal Investigator:||Ronald Hoffman, MD||Mount Sinai School of Medicine|